Placebo News and Research

RSS

NeuroDerm enrolls patients for Phase IIa clinical trial of ND0612

NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its Phase IIa clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease.

16 Apr 2013

L-carnitine improves cardiac health in patients after heart attack, say researchers

L-carnitine significantly improves cardiac health in patients after a heart attack, say a multicenter team of investigators in a study published today in Mayo Clinic Proceedings.

15 Apr 2013

KYTHERA Biopharmaceuticals reports positive results from Phase IIb study of ATX-101

KYTHERA Biopharmaceuticals, Inc. today presented positive results that found MRI measurements of patients treated with ATX-101 demonstrated a statistically significant reduction in submental fat, commonly known as double chin, during an oral session at The Aesthetic Meeting 2013, organized by the American Society for Aesthetic Plastic Surgery, April 11-16, New York, NY.

15 Apr 2013

NCRI, Prize4Life recognized with Bio-IT World's Best Practices Award for creating PRO-ACT platform

The Massachusetts General Hospital Neurological Clinical Research Institute and Prize4Life, a nonprofit organization whose mission is to accelerate the discovery of treatments and a cure for amyotrophic lateral sclerosis, received a Best Practices Award at the 2013 Bio-IT World Conference & Expo.

15 Apr 2013

Two physicians receive Junior Investigator Recognition Awards at Internal Medicine 2013

Annals of Internal Medicine and the American College of Physicians will honor Adrienne Allen, MD, MPH and Matthew Spitzer, MD with the Junior Investigator Recognition Awards at Internal Medicine 2013, the annual scientific meeting of the American College of Physicians.

15 Apr 2013

Dexmedetomidine may be an effective treatment option for opioid-induced hyperalgesia

Surgical patients who demonstrated heightened pain sensitivity, or hyperalgesia, induced by high doses of a synthetic opioid had their symptoms alleviated by co-treatment with dexmedetomidine, according to new research. Study investigators, who presented their results today at the 29th Annual Meeting of the American Academy of Pain Medicine, concluded that dexmedetomidine may be a new and effective treatment option for opioid-induced hyperalgesia (OIH).

12 Apr 2013

Nalmefene can provide important clinical benefit for alcohol-dependent patients

A potential new treatment for alcoholism called nalmefene is effective and safe for reducing alcohol consumption in alcohol dependent individuals, says a new study published this week in Biological Psychiatry.

12 Apr 2013

Migraine severity and adiponectin: an interview with Dr. B. Lee Peterlin, Johns Hopkins University School of Medicine

Migraine affects an estimated 30 million people in the U.S, with the one year prevalence of migraine estimated at 12% of the general population, including 18% of all women and 6% of all men.

12 Apr 2013

Sorbent Therapeutics starts patient dosing in Phase 2b clinical trial of CLP-1001

Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced that patient dosing has commenced in its Phase 2b clinical trial of CLP-1001.

12 Apr 2013

Ohio State researchers use smart phones to evaluate progress of stroke survivors

While many of us take the technology packed into smart phones and tablets for granted, researchers that specialize in rehabilitation are inspired by it, using it to evaluate the progress of stroke survivors who are learning to walk again.

10 Apr 2013

Galectin Therapeutics provides details on first-in-man Phase 1 clinical trial of GR-MD-02

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced details today on its first-in-man Phase 1 clinical trial that will support a proposed indication of GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH, or fatty liver disease) with advanced fibrosis.

10 Apr 2013

REVEAL trial: VASCAZEN meets primary endpoint

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, is pleased to announce that VASCAZEN met its primary endpoint in the REVEAL trial.

10 Apr 2013

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.

10 Apr 2013

Antibiotic drug minocycline yields modest improvements in children with fragile X syndrome

The antibiotic drug minocycline yields "modest" but meaningful improvements in functioning and mood for children with fragile X syndrome (FXS), reports a study in the April Journal of Developmental & Behavioral Pediatrics, the official journal of the Society for Developmental and Behavioral Pediatrics.

9 Apr 2013

ISP of Chile approves Trigemina's protocol for Phase 2 clinical study of TI-001

Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced that the Instituto de Salud Publica of Chile has approved the Company's protocol for its Phase 2 clinical study of TI-001, intranasal oxytocin, for the treatment of chronic migraine.

9 Apr 2013

Argentina's ANMAT approves AUBAGIO for patients with relapsing multiple sclerosis

Genzyme, a Sanofi company, announced today Argentina's National Administration of Drugs, Food and Medical Technology has approved once-daily, oral AUBAGIO 14 mg as a new treatment indicated for patients with relapsing forms of multiple sclerosis.

9 Apr 2013

Diclegis gets FDA approval for treatment of nausea and vomiting of pregnancy

The U.S. Food and Drug Administration today approved Diclegis (doxylamine succinate and pyridoxine hydrochloride) to treat pregnant women experiencing nausea and vomiting.

9 Apr 2013

FDA grants priority review for Bayer HealthCare's riociguat for treatment of CTEPH

Bayer HealthCare announced today that the New Drug Application for its oral investigational compound riociguat has been accepted for filing and granted priority review by the U.S. Food and Drug Administration for the treatment of inoperable chronic thromboembolic pulmonary hypertension or with persistent or recurrent CTEPH after pulmonary endarterectomy and pulmonary arterial hypertension.

8 Apr 2013

KYTHERA Biopharmaceuticals presents Phase IIIb study results of ATX-101

KYTHERA Biopharmaceuticals, Inc. today announced positive interim results from a Phase IIIb, multicenter, open-label study (ATX-101-11-26) of ATX-101 during the "Innovations and Renewals" session of the 11th Anti-Aging Medicine World Congress, April 4-6, Monte Carlo, Monaco.

8 Apr 2013

AstraZeneca reports fostamatinib Phase 3 study results for treatment of rheumatoid arthritis

AstraZeneca today announced top-line results of OSKIRA-1, a Phase 3 study to assess the efficacy and safety of fostamatinib, the first oral spleen tyrosine kinase inhibitor in development for rheumatoid arthritis.

6 Apr 2013

Placebo News and Research

NeuroDerm enrolls patients for Phase IIa clinical trial of ND0612

L-carnitine improves cardiac health in patients after heart attack, say researchers

KYTHERA Biopharmaceuticals reports positive results from Phase IIb study of ATX-101

NCRI, Prize4Life recognized with Bio-IT World's Best Practices Award for creating PRO-ACT platform

Two physicians receive Junior Investigator Recognition Awards at Internal Medicine 2013

Dexmedetomidine may be an effective treatment option for opioid-induced hyperalgesia

Nalmefene can provide important clinical benefit for alcohol-dependent patients

Migraine severity and adiponectin: an interview with Dr. B. Lee Peterlin, Johns Hopkins University School of Medicine

Sorbent Therapeutics starts patient dosing in Phase 2b clinical trial of CLP-1001

Ohio State researchers use smart phones to evaluate progress of stroke survivors

Galectin Therapeutics provides details on first-in-man Phase 1 clinical trial of GR-MD-02

REVEAL trial: VASCAZEN meets primary endpoint

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Antibiotic drug minocycline yields modest improvements in children with fragile X syndrome

ISP of Chile approves Trigemina's protocol for Phase 2 clinical study of TI-001

Argentina's ANMAT approves AUBAGIO for patients with relapsing multiple sclerosis

Diclegis gets FDA approval for treatment of nausea and vomiting of pregnancy

FDA grants priority review for Bayer HealthCare's riociguat for treatment of CTEPH

KYTHERA Biopharmaceuticals presents Phase IIIb study results of ATX-101

AstraZeneca reports fostamatinib Phase 3 study results for treatment of rheumatoid arthritis

Industry Focus eBook - Cell biology (5th edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News